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Plasma liver-enzyme tests are widely used in the clinic for the diagnosis of liver diseases and for monitoring the response to drug treat-
ment. There is considerable evidence that human genetic variation inﬂuences plasma levels of liver enzymes. However, such genetic
variation has not been systematically assessed. In the present study, we performed a genome-wide association study of plasma liver-en-
zyme levels in three populations (total n ¼ 7715) with replication in three additional cohorts (total n ¼ 4704). We identiﬁed two loci
inﬂuencing plasma levels of alanine-aminotransferase (ALT) (CPN1-ERLIN1-CHUK on chromosome 10 and PNPLA3-SAMM50 on chro-
mosome 22), one locus inﬂuencing gamma-glutamyl transferase (GGT) levels (HNF1A on chromosome 12), and three loci for alkaline
phosphatase (ALP) levels (ALPL on chromosome 1, GPLD1 on chromosome 6, and JMJD1C-REEP3 on chromosome 10). In addition, we
conﬁrmed the associations between the GGT1 locus and GGT levels and between the ABO locus and ALP levels. None of the ALP-asso-
ciated SNPs were associated with other liver tests, suggesting intestine and/or bone speciﬁcity. The mechanisms underlying the associ-
ations may involve cis- or trans-transcriptional effects (some of the identiﬁed variants were associated with mRNA transcription in hu-
man liver or lymphoblastoid cells), dysfunction of the encoded proteins (caused by missense variations at the functional domains), or
other unknown pathways. These ﬁndings may help in the interpretation of liver-enzyme tests and provide candidate genes for liver dis-
eases of viral, metabolic, autoimmune, or toxic origin. The speciﬁc associations with ALP levels may point to genes for bone or intestinal
diseases.Plasma liver-enzyme tests are widely used in the clinic to
identify patients with liver diseases, to monitor the course
and severity of these diseases and the effect of therapies,
and to detect drug-induced liver injury.1,2 These tests also
have substantial epidemiologic signiﬁcance that extends
beyond the liver, given that they have been shown to be
prospective risk factors for type 2 diabetes, cardiovascular
disease, and all-cause mortality in multiple large stud-
ies.3–6 Therefore, it is of interest to identify genes or loci af-
fecting these markers in order to establish whether such
loci are also associated with these clinical endpoints.
Plasma liver-enzyme levels are inﬂuenced by environ-
mental and genetic factors. The estimated heritabilities
range from 33% for alanine-aminotransferase (ALT) to
61% for gamma-glutamyl transferase (GGT).7,8 So far,
only a limited number of genes that inﬂuence liver-
enzyme levels have been identiﬁed, mostly those responsi-
ble for Mendelian liver diseases such as mutations in the
HFE gene in hemochromatosis (MIM 235200).9,10 A thor-
ough understanding of the genetic determinants of plasma
liver enzymes is important for proper interpretation ofthese tests. Indeed, such information could assist in our
understanding of the interindividual differences in the
propensity for development of liver dysfunction in the
presence of toxins or conditions such as metabolic syn-
drome. As such, identiﬁcation of genes associated with
liver-enzyme levels could reveal previously unsuspected
candidate genes for liver diseases of viral, metabolic, auto-
immune, or toxic origin.
The goal of the present study was to identify, by using
a genome-wide association (GWA) approach, genes inﬂu-
encing plasma levels of ALT and aspartate-aminotransfer-
ase (AST), two markers of hepatocyte injury and liver fat
accumulation, and of alkaline phosphatase (ALP) and
GGT, used primarily as indicators of biliary or cholestatic
diseases and heavy alcohol consumption.
In the discovery phase, we carried out independent GWA
studies in three population-based cohorts, the CoLaus
Study from Lausanne Switzerland11,12 (n ¼ 5636), the
InCHIANTI Study from Tuscany Italy13 (n ¼ 1200), and
a subset of the LOLIPOP Study from West London
UK14,15 (n ¼ 879) (Table 1). The clinical characteristics of
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Table 1. Description of Six Collections Used in GWAS on Plasma Liver-Enzyme Levels
CoLaus InCHIANTI LOLIPOP
Sample size (n) 5636 1200 879 1006 1005 2693
Location Lausanne,
Switzerland
Tuscany, Italy London, UK London, UK London, UK London, UK
Ethnicity European white European white European white Indian Asian European white Indian Asian
Study Design Population-based Population-based Population-based
enriched with
coronary artery
disease
Nested metabolic
syndrome case
and control
Nested metabolic
syndrome case
and control
Nested metabolic
syndrome case
and control
Data Usage GWA Discovery GWA Discovery GWA Discovery Replication Replication Replication
Liver enzymes AST,a ALT,b GGT,c
and ALPd
AST, ALT,
GGT, ALP
ALT, GGT, ALP ALT, GGT, ALP ALT, GGT, ALP ALT, GGT, ALP
Genotyping
Platform
Affymetrix 500k Illumina
HumanHap550
Affymetrix 500k Perlegen,
custom array
Perlegen,
custom array
Illumina
HumanHap300
Number of SNPs
genotyped
370,697 496,032 387,549 248,537 266,722 317,968
a AST, aspartate aminotransferase.
b ALT, alanine aminotransferase.
c GGT, gamma-glutamyltransferase.
d ALP, alkaline phosphatase.the participants are described in Table 2. The mean levels
of liver-enzyme tests varied somewhat between popula-
tions, presumably because of slight differences in the de-
mographics of the populations under study and methodo-
logical differences in the assays (Table S1 available online).
Accordingly, we used study-speciﬁc criteria for GWA-geno-
typing quality control11,14 and liver-enzyme-level analyses
(Appendix A). Additional genotypes were imputed on the
basis of the HapMap Phase II data with the software
IMPUTE.16 For these imputed data, we performed associa-
tion analysis with SNPTEST, using the full posterior proba-
bility genotype distribution for each study separately
(adding in relevant covariables). Only SNPswith a posterior
probability score >0.90, high genotype information con-
tent (proper_info >0.5), and minor allele frequency >0.01
were considered for these imputed association analyses.
Quantile-quantile plots (Figure 1) revealed the presence
of a substantial number of SNPs associated with ALT,
GGT, and ALP levels at a genome-wide signiﬁcance level
(p value < 107). No SNP with plasma levels of AST was as-
sociated with genome-wide signiﬁcance. It is not clear why
ASTwas uninformative in this case. Highly signiﬁcantly as-
sociated SNPs were located within discrete regions of the
genome (Figure 2), including two loci for ALT (10q24.2
and 22q13.31), two loci for GGT (12q24.31 and
22q11.23), and ﬁve loci for ALP (1p36.12, 6p22.2,
9q34.13, 10q21.2-21.3, and 19q13.33).
A total of 74 Affymetrix-genotyped SNPs (24 for ALT, 8
for GGT, and 42 for ALP, Table S2) with a p value % 105
in the discovery phase was subsequently examined in
3699 Indian Asian and 1005 European white participants
from the LOLIPOP study (Table 1). After joint analysis of
discovery and replication data, 32 SNPs (10 for ALT, 6 for
GGT, and 16 for ALP, Table S3 and Figures S1–S8) reached
genome-wide signiﬁcance with directionally consistent
signals (Figures S9–S16 for the leading SNPs) among theThe Ameridiscovery and replication cohorts. The remaining 42
SNPs were not considered as replicated because of either
lack of high-quality imputation (Appendix A) of the
Table 2. Clinical Characteristics of the Participants in the
Discovery Data Sets from CoLaus, InCHIANTI, and LOLIPOP
Population-Based Studies
CoLausa InCHIANTIa LOLIPOPa
n 5636 1200 879b
Sex (% F) 52.8 55.2 23.0
Age (years) 53.25 10.8 68.45 15.9 52.8 5 10.4
Fasting glucose
(mmol/L)
5.565 1.16 5.245 1.36 5.50 5 1.54
Insulin (mIU/mL) 8.765 6.25 10.95 6.15 10.3 5 10.7
BMI (kg/m2) 25.85 4.6 27.15 4.1 27.9 5 4.8
Waist (cm) 89.35 13.4 NA 96.7 5 13.0
Hip (cm) 101.05 9.3 NA 103.05 9.0
Total cholesterol
(mmol/L)
5.605 1.04 NA 5.32 5 1.07
LDL-cholesterol
(mmol/L)
3.345 0.92 3.435 0.90 3.25 5 0.93
Triglycerides
(mmol/L)
1.405 1.20 1.425 0.88 1.61 5 1.16
HDL-cholesterol
(mmol/L)
1.645 0.44 1.435 0.39 1.36 5 0.35
Albumin (g/L) 44.25 2.5 42.35 3.2 43.6 5 2.9
Smoking status
(% smokers)
11.8 18.8 64.4
Alcohol
consumption (%)c
77.3 NA 75.7
Type 2 Diabetes (%) 6.6 11.1 11.3
AST (U/L) 29.75 13.5 20.25 0.4 NA
ALT (U/L) 27.65 19.5 18.15 0.5 29.1 5 16.4
ALP (U/L) 63.45 20.4 204.25 71.5 80.9 5 38.5
GGT (U/L) 32.15 39.9 26.25 28.7 40.2 5 44.8
a Results are expressed as mean 5 SD.
b Subset from the LOLIPOP population-based study enriched with CAD
cases.
c Alcohol consumption was defined as alcohol intakeR1 unit per week.can Journal of Human Genetics 83, 520–528, October 10, 2008 521
Figure 1. Quantile-Quantile Plot for GWA for ALT, GGT, ALP, and AST in a Meta-analysis from CoLaus, InCHIANTI, and LOLIPOP
Discovery Study Data Sets with Imputed Autosomal SNPs
The blue and red dotted lines correspond to 95% CI and 99% CI, respectively. Each panel shows data for the enzymes as follows: (A), ALT;
(B), GGT; (C), ALP; and (D), AST.presence of inconsistent direction of the effect across stud-
ies or because they did not reach genome-wide signiﬁcance
level (p% 108). It is also conceivable that absence of rep-
lication was due to LD differences between the European
white and Indian Asian cohorts. Out of the 32 replicated
SNPs, 19 SNPs were considered to be independent (r2 <
0.4) (Table 3). These SNPs were located within two loci
for ALT, two loci for GGT, and four loci for ALP.522 The American Journal of Human Genetics 83, 520–528, OctobeThe ALT-associated 10q24.2 region (Figure S1) spans
three genes. CHUK (IKK-a) is a ubiquitously expressed
serine threonine protein kinase that modulates the NF-
kB-transcription-factor-dependent activation of several
genes implicated in insulin resistance. Its intronic SNP
rs11591741 has been reported to be associated with expres-
sion of its upstream gene CWF19L1 (CWF19-like 1) in
human liver (p ¼ 1.47 3 1039),17 probably through itsr 10, 2008
Figure 2. GWA Analysis of ALT, GGT, and ALP
Represented here are three Manhattan plots showing the degree of association (log10 p value) between imputed SNPs included in the
meta-analysis of three discovery collections totaling 7715 individuals. Red dots correspond to the SNPs with p value % 108.transcriptional regulatory effect. CPN1 encodes arginine
carboxypeptidase-1, a liver-expressed plasma metallo-
protease that protects the body from potent vasoactive
and inﬂammatory peptides containing C-terminal argi-
nine or lysine (such as kinins or anaphylatoxins), which
are released into the circulation.18,19 Defects in CPN1 are
the cause of carboxypeptidase N deﬁciency (MIM
212070). ERLIN1 encodes a member of the prohibitin fam-
ily of proteins that deﬁne lipid-raft-like domains of the en-
doplasmic reticulum.20 The second association peak for
ALT on chromosome 22q13.31 (Figure S2) encompasses
a 57 kb fragmented linkage disequilibrium (LD) region
encompassing SAMM50 and PNPLA3. SAMM50 is
a subunit of mitochondrial SAM translocase complex for
importation of proteins such as metabolite-exchange
anion-selective channel precursors,21,22 whose N-terminal
domain is essential for the biogenesis of mitochondria. The
variation of imputed SNP rs3761472 (p ¼ 2.7 3 109)
causes N-terminal Asp110Glu substitution in SAMM50,
which may lead to mitochondrial dysfunction and im-
paired cell growth. PNPLA3 (ADPN) is a liver-expressed
transmembrane protein with phospholipase activity.23 It
has been shown to be signiﬁcantly upregulated during ad-
ipocyte differentiation, and in response to fasting and
feeding, indicating its role in facilitating both energy mo-
bilization and lipid storage in adipose and liver.24 PNPLA3
mRNA expression was elevated in subcutaneous and vis-The Americceral adipose tissue of obese subjects.25 The lead SNP
rs2281135 is in complete LD (r2 ¼ 1) with intronic SNPs
rs1010022 and rs2072907, two obesity-associated tagSNPs
that showed signiﬁcant differences in adipose PNPLA3
mRNA expression and adipocyte lipolysis from experimen-
tal data.25 Two imputed nonsynonymous SNPs within
PNPLA3 (rs738409 [Ile148Met], p ¼ 3.7 3 1010, and
rs2294918 [Lys434Glu], p ¼ 6.0 3 104), represent puta-
tive exonic splicing silencer elements and might play
a role in gene regulation.26 Homozygous carriers of the
GG genotype for rs2281135 had a 34% greater risk (OR
1.34 [1.13–1.60]) of having ALT levels above upper limits
of normal (deﬁned as 36 U/L in females, and 60 U/L in
males) in the CoLaus study. The effect of the lead SNPs at
both CPN1 and PNPLA3 loci was not speciﬁc for ALT be-
cause these SNPs were also associated with plasma levels
of AST (Table 4), suggesting that these genes are generally
predisposed to hepatocyte dysfunction.
When examining the association with GGT levels, we
identiﬁed a series of SNPs within 300 kb on either side
of the gene encoding GGT1 on chromosomal region
22q11.23 (Figure S3). As such, these SNPs met the deﬁni-
tion of cis-acting SNPs.27 The typed rs4820599 (p ¼ 4.0 3
1011) is in high LD with previously reported variant
rs5751901 (r2 ¼ 0.71) associated with serum GGT13 and
with rs6519519 (r2 ¼ 0.96), a SNP associated with tran-
script abundance in lymphoblastoid cells;28 such a ﬁndingan Journal of Human Genetics 83, 520–528, October 10, 2008 523
Table 3. Independent SNPs Associated with Liver-Enzyme Levels with Genome-wide Significance in Combined GWAS Analysis of
Discovery and Replication Data Sets
SNPa CHR Positionb
Nearest
Gene Region
Minor
Allelec MAFd
Three Discovery
Collections (n ¼ 7,715)
Three Replication
Collections (n ¼ 4,704)
Six Collections
(n ¼ 12,419)
Pooled Beta-
Coefficient
(standard
error)
Combined
p Value
Pooled Beta-
Coefficient
(standard
error)
Combined
p Value
Pooled Beta-
Coefficient
(standard
error)
Combined
p Value
ALT
rs11597390 10 101851425 CPN1 intergenic A 0.36 0.044
(0.008)
2.9 3 108 0.023
(0.013)
0.08 0.039
(0.007)
1.5 3 108
rs11597086 10 101943695 CHUK Intronic C 0.43 0.038
(0.007)
3.6 3 107 0.030
(0.012)
0.01 0.036
(0.006)
1.8 3 108
rs11591741 10 101966491 CHUK intronic C 0.43 0.038
(0.007)
4.5 3 107 0.029
(0.012)
0.02 0.035
(0.006)
3.0 3 108
rs2281135 22 42657471 PNPLA3 intronic T 0.18 0.065
(0.010)
8.2 3 1012 0.051
(0.012)
1.3 3 105 0.060
(0.007)
8.4 3 1016
rs2143571 22 42716587 SAMM50 intronic A 0.19 0.046
(0.009)
9.4 3 107 0.038
(0.012)
1.8 3 103 0.043
(0.007)
7.2 3 109
GGT
rs1169313 12 119905390 HNF1A intronic C 0.38 0.007
(0.001)
3.2 3 108 0.003
(0.001)
7.0 3 105 0.005
(0.001)
1.8 3 1010
rs4820599 22 23314767 GGT1 intronic G 0.31 0.006
(0.001)
3.9 3 106 0.008
(0.002)
1.8 3 106 0.007
(0.001)
4.0 3 1011
ALP
rs1780324 1 21567063 NBPF3-ALPL intergenic T 0.43 0.032
(0.005)
1.4 3 1010 0.031
(0.007)
1.0 3 105 0.031
(0.004)
7.0 3 1015
rs9461011 6 24548330 GPLD1 intronic G 0.23 0.033
(0.006)
4.4 3 108 0.030
(0.009)
0.001 0.032
(0.005)
1.9 3 1010
rs9467160 6 24549725 GPLD1 intronic A 0.24 0.033
(0.006)
2.2 3 108 0.035
(0.009)
1.3 3 104 0.034
(0.005)
1.2 3 1011
rs8176720 9 133162427 ABO synonymous G 0.32 0.031
(0.005)
1.4 3 108 0.031
(0.008)
7.0 3 105 0.031
(0.004)
4.3 3 1012
rs641959 9 133163253 ABO intronic G 0.26 0.035
(0.006)
6.8 3 1010 0.024
(0.008)
0.004 0.031
(0.005)
2.1 3 1011
rs514708 9 133163297 ABO intronic T 0.26 0.035
(0.006)
6.2 3 1010 0.024
(0.008)
0.004 0.031
(0.005)
1.9 3 1011
rs672316 9 133167679 ABO intronic C 0.27 0.032
(0.006)
1.4 3 108 0.023
(0.008)
0.006 0.029
(0.005)
4.4 3 1010
rs657152 9 133168819 ABO intronic T 0.39 0.057
(0.005)
4.6 3 1029 0.029
(0.007)
4.9 3 105 0.047
(0.004)
1.7 3 1030
rs474279 9 133169171 ABO intronic T 0.24 0.030
(0.006)
3.4 3 107 0.023
(0.008)
0.006 0.028
(0.005)
8.3 3 109
rs552148 9 133183035 ABO upstream T 0.24 0.032
(0.006)
3.1 3 108 0.022
(0.008)
0.008 0.029
(0.005)
1.2 3 109
rs12355784 10 64791571 JMJD1C intronic A 0.48 0.026
(0.005)
4.7 3 107 0.025
(0.007)
2.7 3 104 0.025
(0.004)
5.0 3 1010
rs10761779 10 64944933 REEP3 intergenic G 0.49 0.025
(0.005)
3.9 3 107 0.024
(0.007)
4.5 3 104 0.025
(0.004)
6.9 3 1010
a Independent SNPs (r2 < 0.4) were selected from each loci.
b Position is of NCBI Build 35.
c Minor allele corresponds to forward strand and is of NCBI Build 35.
d MAF, Minor allele frequency. It is based on CoLaus study.suggests that the genetic association observed here is due
to differential expression of the gene. Another association
peak was observed on chromosomal region 12q24.31
(Figure S4) encompassing HNF1A (TCF-1), the hepatic
nuclear factor predominantly expressed in the human
liver. This transcriptional regulatory protein plays a promi-524 The American Journal of Human Genetics 83, 520–528, Octobernent role in the activation of a large family of hepatocyte-
speciﬁc genes involved in hepatocyte differentiation and
liver development.29,30 Mutations within this gene are
associated with type III form of maturity-onset diabetes
of the young (MODY3 [MIM 600496])31 and hepatic ade-
nomas, which are frequently accompanied by an elevation10, 2008
Table 4. Association of the Lead SNPs with Plasma Levels of Liver Enzymes in the CoLaus Study
SNP
Nearest
Gene
ALT AST ALP GGT
Beta
(% 95 CI) p Value
Beta
(% 95 CI) p Value
Beta
(% 95 CI) p Value
Beta
(% 95 CI) p Value
rs11597390 CPN1 0.043
(0.062–0.023)
1.4 3 105 0.022
(0.035–0.009)
0.0009 0.011
(0.023–0.001)
0.08 0.004
(0.008–0.0001)
0.04
rs2281135 PNPLA3 0.064
(0.041–0.087)
2.6 3 108 0.035
(0.020–0.050)
5.7 3 106 0.005
(0.019–0.010)
0.51 0.001
(0.006–0.003)
0.61
rs1169313 HNF1A 0.002
(0.016–0.019)
0.86 0.001
(0.011–0.012)
0.92 0.013
(0.002–0.024)
0.03 0.006
(0.009–0.002)
0.0009
rs4820599 GGT1 0.002
(0.021–0.017)
0.82 0.003
(0.009–0.016)
0.6 0.006
(0.006–0.018)
0.36 0.003
(0.001–0.007)
0.09
rs1780324 NBPF3-ALPL 0.01
(0.007–0.027)
0.26 0.015
(0.003–0.026)
0.01 0.031
(0.020–0.042)
5.6 3 108 0.003
(0.001–0.006)
0.14
rs9467160 GPLD1 0.003
(0.018–0.024)
0.76 0.003
(0.017–0.011)
0.66 0.031
(0.018–0.044)
5.6 3 106 0.001
(0.003–0.005)
0.65
rs657152 ABO 0.012
(0.007–0.030)
0.21 0.001
(0.013–0.011)
0.88 0.061
(0.072–0.050)
2.5 3 1025 0.001
(0.002–0.005)
0.57
rs12355784 JMJD1C 0.003
(0.021–0.015)
0.72 0.001
(0.011–0.013)
0.83 0.026
(0.014–0.037)
1.6 3 105 0.003
(0.001–0.007)
0.1in plasma GGT level (MIM 142330).32 SNP rs7953249 (p ¼
5.13 108) was also closely associated in the CoLaus study
with plasma C-reactive protein levels (p ¼ 4.4 3 1010),
consistent with recently reported observations.33 It is con-
ceivable that variants within this gene, including imputed
rs2464196 (Ser487Asn, p¼ 3.23 1012) located within the
C-terminal transactivation domain of HNF1A,may broadly
affect the transcriptional effect of this nuclear factor.
The strongest association with ALP levels was observed
within the ABO locus on chromosome 9q34.13
(Figure S5). Association between ALP levels and the
ABO blood group has been reported previously.34 This as-
sociation was speciﬁc to plasma ALP (Table 4) with SNP
rs657152 (p ¼ 1.7 3 1030) accounting for 2% of the to-
tal variance of ALP levels in the CoLaus study (Table S4).
The mechanism underlying this association remains un-
clear and may be due to genetically determined varia-
tions in the proportion of isoenzymes among different
blood types because it has been shown that the appear-
ance of intestinal ALP in the plasma, particularly after
fatty meals, is associated with ABO blood group and se-
cretor status.35 In addition, we detected a strong associa-
tion with the ALPL locus (Figure S6), which encodes non-
speciﬁc alkaline phosphatase found in liver, bone,
kidney, and other tissues and is responsible for hypo-
phosphatasia.36 Association of orthologous ALPL gene
with serum ALP levels has been reported in mice37 but
not in humans. One cis-acting SNP rs1780324 within
ALPL had been shown to markedly affect the gene ex-
pression in lymphoblastoid cells.28 One trans-acting sig-
nal was identiﬁed within GPLD1 (glycosylphosphatidylino-
sitol speciﬁc phospholipase D1) gene (Figure S7). GPLD1
hydrolyzes the inositol phosphate linkage in proteins an-
chored by phosphatidylinositol glycans (GPI-anchor),
thus releasing these proteins from the membrane. Ele-
vated serum levels of GPLD1 and hepatic mRNA expres-The Americsion have been reported in nonalcoholic fatty liver dis-
ease (NAFLD).38 Finally, one additional trans-acting SNP
was localized in the JMJD1C (TRIP8)-REEP3 (receptor acces-
sory protein 3) region. JMJD1C encodes thyroid-hormone-
receptor interactor 8, a hormone-dependent transcription
factor that regulates expression of a variety of speciﬁc tar-
get genes39 (Figure S8). The observation that none of the
ALP-associated genes were crossassociated with other
liver enzymes (Table 4) may indicate that the association
signal was generated by variations in bone- or intestine-
rather than liver-metabolic pathways.40
The ﬁndings reported here were generated on a limited
number of genome-wide scans, and it is anticipated that
adding more scans with enriched liver phenotypes within
the discovery and replication phase will further expand the
number of genes and loci associated with plasma liver-en-
zyme levels in the population.
At this stage, the discovery of ﬁve trans-acting loci and
one cis-acting locus inﬂuencing plasma levels of liver en-
zymes may point to mechanisms regulating these enzymes
and could assist in the interpretation of liver tests in the
clinic. Most importantly, these genes represent candidates
for susceptibility to liver diseases. Analysis between vari-
ants within these genes and NAFLD, alcohol-, viral, auto-
immune, or toxin-induced liver injury is warranted.
Appendix A
Material and Methods
Study Populations. The CoLaus study is a population-based
sample consisting of 5694 Lausanne residents aged 35 to
75 years. The study design and protocol have been de-
scribed previously.11,12,42
The London Life Sciences Population (LOLIPOP) study is
an ongoing population-based cohort study of ~30,000an Journal of Human Genetics 83, 520–528, October 10, 2008 525
Indian Asian and European white men and women, aged
35–75 years, recruited from the lists of 58 general practi-
tioners in West London, United Kingdom.14,15 The partic-
ipants included in the present study are a subset of the
LOLIPOP cohort study. These subsets were assembled for
speciﬁc experiments for identiﬁcation of genetic variants
underlying metabolic syndrome and coronary artery dis-
ease (CAD). The samples were genotyped on separate plat-
forms (Table 1).
The InCHIANTI study is a population-based sample that
includes 1200 individuals of <65 age and 1155 individuals
of ageR65 years. Details of the study design and protocol
have been described previously.13 A total of 1200 subjects
who had bothWGS data and liver-enzyme levels measured
were included in this study.
Genome-wide Association Statistics. Linear-regression
analyses were done on natural log-transformed ALT, ALP,
and AST and power-transformed GGT independently in
each study. Regression analyses were done with the PLINK
software package43 adjusted by age, gender, and geograph-
ical principle components analyzed by EIGENSOFT soft-
ware,44 plus smoking and alcohol intake if they were
signiﬁcant covariates for the trait.
Imputation. For CoLaus, InCHIANTI, and LOLIPOP dis-
covery set genotypes were imputed separately on the basis
of the HapMap Phase II build35 data with the software
IMPUTE.16 For these imputed data, we performed associa-
tion analysis with SNPTEST, using the full posterior-
probability genotype distribution for each study separately
(adding in relevant covariables). Only SNPswith a posterior
probability score >0.90, high genotype information con-
tent (proper_info >0.5), and MAF >0.01 were consid-
ered for the imputed association analyses. SNP imputa-
tion for LOLIPOP substudies used the MACH program
(v1.0). For European data sets, CEPH haplotypes in
HapMap were used as reference haplotypes. Indian
Asian data sets were imputed on the basis of a combina-
tion (mixed) of HapMap populations, given that this
showed greater concordance with real genotypes, com-
pared with use of any one HapMap population. Imputa-
tion analyses were based on HapMap build35, dbSNP
build 125. Only SNPs with RSQR R0.3 were considered
for the meta-analysis.
Meta-analysis. For the initial GWA screen, analyses
were performed within study, with study-speciﬁc criteria
for GWA-genotyping QC and analyses (as described
above). We meta-analyzed these summary data by using
a ﬁxed-effects model and inverse-variance weighted
averages of beta-coefﬁcients to obtain a combined esti-
mate of the overall beta-coefﬁcient and its standard
error. Among-study heterogeneity was assessed with the
c2 test.
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support/technical/whitepapers/brlmmwhitepaper.pdf
EIGENSOFT software, http://genepath.med.harvard.edu/~reich/
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MACH, http://www.sph.umich.edu/csg/abecasis/MACH/
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References
1. Lazo, M., Selvin, E., and Clark, J.M. (2008). Brief communica-
tion: Clinical implications of short-term variability in liver
function test results. Ann. Intern. Med. 148, 348–352.
2. Wilke, R.A., Lin, D.W., Roden, D.M., Watkins, P.B., Flockhart,
D., Zineh, I., Giacomini, K.M., and Krauss, R.M. (2007). Identi-
fying genetic risk factors for serious adverse drug reactions: Cur-
rent progress andchallenges.Nat. Rev.DrugDiscov.6, 904–916.
3. Forlani, G., Di Bonito, P., Mannucci, E., Capaldo, B., Genovese,
S., Orrasch, M., Scaldaferri, L., Di Bartolo, P., Melandri, P., Dei
Cas, A., et al. (2008). Prevalence of elevated liver enzymes in
Type 2 diabetes mellitus and its association with themetabolic
syndrome. J. Endocrinol. Invest. 31, 146–152.
4. Lee, D.H., Silventoinen, K., Hu, G., Jacobs, D.R., Jr., Jousilahti,
P., Sundvall, J., and Tuomilehto, J. (2006). Serum gamma-
glutamyltransferase predicts non-fatal myocardial infarction
and fatal coronary heart disease among 28,838 middle-aged
men and women. Eur. Heart J. 27, 2170–2176.r 10, 2008
5. Monami, M., Bardini, G., Lamanna, C., Pala, L., Cresci, B.,
Francesconi, P., Buiatti, E., Rotella, C.M., and Mannucci, E.
(2008). Liver enzymes and risk of diabetes and cardiovascular
disease: Results of the Firenze Bagno a Ripoli (FIBAR) study.
Metabolism 57, 387–392.
6. Kazemi-Shirazi, L., Endler, G., Winkler, S., Schickbauer, T.,
Wagner, O., and Marsik, C. (2007). Gamma glutamyltransfer-
ase and long-term survival: Is it just the liver? Clin. Chem. 53,
940–946.
7. Bathum, L., Petersen, H.C., Rosholm, J.U., Hyltoft Petersen, P.,
Vaupel, J., and Christensen, K. (2001). Evidence for a substan-
tial genetic inﬂuence on biochemical liver function tests:
Results from a population-based Danish twin study. Clin.
Chem. 47, 81–87.
8. Whitﬁeld, J.B., Zhu, G., Nestler, J.E., Heath, A.C., and Martin,
N.G. (2002). Genetic covariation between serum gamma-
glutamyltransferase activity and cardiovascular risk factors.
Clin. Chem. 48, 1426–1431.
9. Adams, P.C., and Barton, J.C. (2007). Haemochromatosis. Lan-
cet 370, 1855–1860.
10. Stepec, S., Makuc, J., Markovic, S., Medica, I., and Peterlin, B.
(2008). Distribution of HFE gene mutations in Slovenian
patients with hereditary hemochromatosis. Ann. Hematol.
87, 667–669.
11. Loos, R.J., Lindgren, C.M., Li, S., Wheeler, E., Zhao, J.H.,
Prokopenko, I., Inouye, M., Freathy, R.M., Attwood, A.P.,
Beckmann, J.S., et al. (2008). Common variants near MC4R
are associated with fat mass, weight and risk of obesity. Nat.
Genet. 40, 768–775.
12. Sandhu, M.S., Waterworth, D.M., Debenham, S.L., Wheeler,
E., Papadakis, K., Zhao, J.H., Song, K., Yuan, X., Johnson, T.,
Ashford, S., et al. (2008). LDL-cholesterol concentrations: A
genome-wide association study. Lancet 371, 483–491.
13. Melzer, D., Perry, J.R., Hernandez, D., Corsi, A.M., Stevens, K.,
Rafferty, I., Lauretani, F., Murray, A., Gibbs, J.R., Paolisso, G.,
et al. (2008). A genome-wide association study identiﬁes pro-
tein quantitative trait loci (pQTLs). PLoS Genet. 4, e1000072.
14. Chambers, J.C., Elliott, P., Zabaneh, D., Zhang, W., Li, Y.,
Froguel, P., Balding, D., Scott, J., and Kooner, J.S. (2008). Com-
mon genetic variation near MC4R is associated with waist cir-
cumference and insulin resistance. Nat. Genet. 40, 716–718.
15. Kooner, J.S., Chambers, J.C., Aguilar-Salinas, C.A., Hinds,
D.A., Hyde, C.L., Warnes, G.R., Gomez Perez, F.J., Frazer,
K.A., Elliott, P., Scott, J., et al. (2008). Genome-wide scan iden-
tiﬁes variation in MLXIPL associated with plasma triglycer-
ides. Nat. Genet. 40, 149–151.
16. Marchini, J., Howie, B., Myers, S., McVean, G., and Donnelly,
P. (2007). A new multipoint method for genome-wide associ-
ation studies by imputation of genotypes. Nat. Genet. 39,
906–913.
17. Schadt, E.E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum,
P.Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., et al.
(2008). Mapping the genetic architecture of gene expression
in human liver. PLoS Biol. 6, e107.
18. Skidgel, R.A., Bennett, C.D., Schilling, J.W., Tan, F.L., Weera-
singhe, D.K., and Erdos, E.G. (1988). Amino acid sequence
of the N-terminus and selected tryptic peptides of the active
subunit of human plasma carboxypeptidase N: Comparison
with other carboxypeptidases. Biochem. Biophys. Res. Com-
mun. 154, 1323–1329.The Ameri19. Matthews, K.W., Mueller-Ortiz, S.L., and Wetsel, R.A. (2004).
Carboxypeptidase N: A pleiotropic regulator of inﬂammation.
Mol. Immunol. 40, 785–793.
20. Browman, D.T., Resek, M.E., Zajchowski, L.D., and Robbins,
S.M. (2006). Erlin-1 and erlin-2 are novel members of the pro-
hibitin family of proteins that deﬁne lipid-raft-like domains of
the ER. J. Cell Sci. 119, 3149–3160.
21. Kutik, S., Stojanovski, D., Becker, L., Becker, T., Meinecke, M.,
Kruger, V., Prinz, C., Meisinger, C., Guiard, B., Wagner, R.,
et al. (2008). Dissectingmembrane insertion of mitochondrial
beta-barrel proteins. Cell 132, 1011–1024.
22. Kozjak, V., Wiedemann, N., Milenkovic, D., Lohaus, C.,
Meyer, H.E., Guiard, B., Meisinger, C., and Pfanner, N.
(2003). An essential role of Sam50 in the protein sorting and
assembly machinery of the mitochondrial outer membrane.
J. Biol. Chem. 278, 48520–48523.
23. Wilson, P.A., Gardner, S.D., Lambie, N.M., Commans, S.A.,
and Crowther, D.J. (2006). Characterization of the human pa-
tatin-like phospholipase family. J. Lipid Res. 47, 1940–1949.
24. Moldes, M., Beauregard, G., Faraj, M., Peretti, N., Ducluzeau,
P.H., Laville, M., Rabasa-Lhoret, R., Vidal, H., and Clement,
K. (2006). Adiponutrin gene is regulated by insulin and glu-
cose in human adipose tissue. Eur. J. Endocrinol. 155,
461–468.
25. Johansson, L.E., Hoffstedt, J., Parikh, H., Carlsson, E.,
Wabitsch, M., Bondeson, A.G., Hedenbro, J., Tornqvist, H.,
Groop, L., and Ridderstrale, M. (2006). Variation in the adipo-
nutrin gene inﬂuences its expression and associates with obe-
sity. Diabetes 55, 826–833.
26. Yuan, H.Y., Chiou, J.J., Tseng, W.H., Liu, C.H., Liu, C.K., Lin,
Y.J., Wang, H.H., Yao, A., Chen, Y.T., and Hsu, C.N. (2006).
FASTSNP: An always up-to-date and extendable service for
SNP function analysis and prioritization. Nucleic Acids Res.
34, W635–W641.
27. Stranger, B.E., Forrest, M.S., Clark, A.G., Minichiello, M.J.,
Deutsch, S., Lyle, R., Hunt, S., Kahl, B., Antonarakis, S.E.,
Tavare, S., et al. (2005). Genome-wide associations of gene ex-
pression variation in humans. PLoS Genet. 1, e78.
28. Dixon, A.L., Liang, L., Moffatt, M.F., Chen, W., Heath, S.,
Wong, K.C., Taylor, J., Burnett, E., Gut, I., Farrall, M., et al.
(2007). A genome-wide association study of global gene ex-
pression. Nat. Genet. 39, 1202–1207.
29. Cereghini, S., Yaniv, M., and Cortese, R. (1990). Hepatocyte
dedifferentiation and extinction is accompanied by a block
in the synthesis of mRNA coding for the transcription factor
HNF1/LFB1. EMBO J. 9, 2257–2263.
30. Frain, M., Swart, G., Monaci, P., Nicosia, A., Stampﬂi, S., Frank,
R., and Cortese, R. (1989). The liver-speciﬁc transcription fac-
tor LF-B1 contains a highly diverged homeobox DNA binding
domain. Cell 59, 145–157.
31. Bellanne-Chantelot, C., Carette, C., Riveline, J.P., Valero, R.,
Gautier, J.F., Larger, E., Reznik, Y., Ducluzeau, P.H., Sola, A.,
Hartemann-Heurtier, A., et al. (2008). The type and the posi-
tion of HNF1Amutationmodulate age at diagnosis of diabetes
in patients with maturity-onset diabetes of the young
(MODY)-3. Diabetes 57, 503–508.
32. Bluteau, O., Jeannot, E., Bioulac-Sage, P., Marques, J.M., Blanc,
J.F., Bui, H., Beaudoin, J.C., Franco, D., Balabaud, C.,
Laurent-Puig, P., et al. (2002). Bi-allelic inactivation of TCF1
in hepatic adenomas. Nat. Genet. 32, 312–315.
33. Reiner, A.P., Barber, M.J., Guan, Y., Ridker, P.M., Lange, L.A.,
Chasman, D.I., Walston, J.D., Cooper, G.M., Jenny, N.S.,can Journal of Human Genetics 83, 520–528, October 10, 2008 527
Rieder, M.J., et al. (2008). Polymorphisms of the HNF1A gene
encoding hepatocyte nuclear factor-1 alpha are associated
with C-reactive protein. Am. J. Hum. Genet. 82, 1193–1201.
34. Whitﬁeld, J.B., and Martin, N.G. (1983). Determinants of var-
iation in plasma alkaline phosphatase activity: A twin study.
Am. J. Hum. Genet. 35, 978–986.
35. Walker, B.A., Eze, L.C., Tweedie, M.C., and Evans, D.A. (1971).
The inﬂuence of ABO blood groups, secretor status and fat in-
gestion on serum alkaline phosphatase. Clin. Chim. Acta 35,
433–444.
36. Brun-Heath, I., Lia-Baldini, A.S., Maillard, S., Taillandier, A.,
Utsch, B., Nunes, M.E., Serre, J.L., and Mornet, E. (2007). De-
layed transport of tissue-nonspeciﬁc alkaline phosphatase
with missense mutations causing hypophosphatasia. Eur. J.
Med. Genet. 50, 367–378.
37. Foreman, J.E., Blizard, D.A., Gerhard, G., Mack, H.A., Lang,
D.H., Van Nimwegen, K.L., Vogler, G.P., Stout, J.T., Shihabi,
Z.K., Grifﬁth, J.W., et al. (2005). Serum alkaline phosphatase
activity is regulated by a chromosomal region containing
the alkaline phosphatase 2 gene (Akp2) in C57BL/6J and
DBA/2J mice. Physiol. Genomics 23, 295–303.
38. Chalasani, N., Vuppalanchi, R., Raikwar, N.S., and Deeg, M.A.
(2006). Glycosylphosphatidylinositol-speciﬁc phospholipase
d in nonalcoholic Fatty liver disease: A preliminary study. J.
Clin. Endocrinol. Metab. 91, 2279–2285.528 The American Journal of Human Genetics 83, 520–528, October39. Lee, J.W., Choi, H.S., Gyuris, J., Brent, R., and Moore, D.D.
(1995). Two classes of proteins dependent on either the pres-
ence or absence of thyroid hormone for interaction with the
thyroid hormone receptor. Mol. Endocrinol. 9, 243–254.
40. Christenson, R.H. (1997). Biochemical markers of bone me-
tabolism: An overview. Clin. Biochem. 30, 573–593.
41. Ge, D., Zhang, K., Need, A.C., Martin, O., Fellay, J., Urban, T.J.,
Telenti, A., and Goldstein, D.B. (2008). WGAViewer: Software
for genomic annotation of whole genome association studies.
Genome Res. 18, 640–643.
42. Firmann, M., Mayor, V., Vidal, P.M., Bochud, M., Pecoud, A.,
Hayoz, D., Paccaud, F., Preisig, M., Song, K.S., Yuan, X., et al.
(2008). The CoLaus study: A population-based study to
investigate the epidemiology and genetic determinants of car-
diovascular risk factors and metabolic syndrome. BMC Cardi-
ovasc. Disord. 8, 6.
43. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., et al. (2007). PLINK: A tool set for whole-genome associ-
ation and population-based linkage analyses. Am. J. Hum.
Genet. 81, 559–575.
44. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E.,
Shadick, N.A., and Reich, D. (2006). Principal components
analysis corrects for stratiﬁcation in genome-wide association
studies. Nat. Genet. 38, 904–909.10, 2008
